Physician profile
Rhonda Strunk
NPI 1659374940
$6,765.41
in general payments reported to CMS, 2019-2025
22 companies · $736 in 2025
The $736 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $101 · 2022: $2,075 · 2023: $1,543 · 2024: $2,311 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,525 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,524.87 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $879.15 | 2022-2025 | Opzelura, Opzelura |
| Sun Pharmaceutical Industries INC. | $789.18 | 2022-2025 | Winlevi, Absorica Ld, Ilumya |
| Abbvie INC. | $754.33 | 2022-2024 | |
| Janssen Biotech, INC. | $718.23 | 2022-2024 | Tremfya |
| Ucb, INC. | $499.44 | 2021-2025 | Bimzelx |
| Lilly USA, LLC | $412.02 | 2022-2024 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $397.01 | 2023-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $318.87 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $248.67 | 2023-2024 | Zoryve |
| Pfizer INC. | $241.12 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $226.97 | 2022-2024 | Dupixent |
| Genzyme Corporation | $176.68 | 2023-2025 | |
| Dermavant Sciences, INC. | $145.60 | 2023-2024 | Vtama |
| Epi Health, LLC | $136.00 | 2022 | |
| Leo Pharma INC. | $134.95 | 2023-2025 | Adbry |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $133.48 | 2024 | Otezla |
| Janssen Pharmaceuticals, INC | $125.00 | 2023 | Spravato |
| Janssen Scientific Affairs, LLC | $123.83 | 2024 | Tremfya |
| Neurocrine Biosciences, INC. | $118.02 | 2025 | |
| Medtronic, INC. | $105.87 | 2022-2024 | Venaseal |
| Organogenesis INC. | $59.04 | 2021-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.95 | 2024 | Jublia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhonda Strunk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.